GIP

GIP receptor (GIPR) is a Gs-coupled GPCR expressed on pancreatic beta-cells, adipocytes, osteoblasts, and in the brain. In beta-cells, GIPR activation elevates cAMP, activating PKA and Epac2 to potentiate glucose-stimulated insulin secretion (GSIS). This incretin effect accounts for 50-70% of postprandial insulin secretion in healthy individuals (the "incretin effect"). In adipocytes, GIPR activation promotes lipid storage (lipogenesis) and inhibits lipolysis, the basis for GIP's historical reputation as a "fat-storage hormone" that worsened obesity. However, the paradoxical weight loss with GIPR agonism in tirzepatide reflects that central GIPR signaling (hypothalamus, area postrema) actually reduces food intake and body weight when combined with GLP-1R activation.

The resolution of the GIP paradox comes from understanding context and receptor location. Peripheral GIPR agonism (adipose tissue) does favor fat storage. But central GIPR agonism (hypothalamic neurons) reduces food intake. GIPR antagonism in rodents promotes weight loss by blocking adipose fat storage; GIPR agonism in tirzepatide also produces weight loss, apparently via dominant central effects. The GLP-1R component of tirzepatide may also facilitate the central weight-reducing effects of GIPR by upregulating GIPR expression on hypothalamic neurons. This represents one of the most counterintuitive pharmacological findings in recent metabolic research.

GIPR is expressed in osteoblasts, where GIP promotes bone formation and inhibits bone resorption, a bone anabolic effect separate from its metabolic actions. GIP knockout mice have reduced bone mineral density and increased fracture susceptibility. Cardiovascular GIPR expression contributes to direct cardioprotective effects: GIP reduces cardiomyocyte apoptosis and improves post-MI recovery in animal models. In the brain, GIPR activation has neuroprotective properties in Alzheimer's and Parkinson's models, promoting neurotrophic factor expression and reducing neuroinflammation.

Tirzepatide's SURMOUNT trial showed 20.9% average weight loss at 72 weeks (vs 3.1% placebo), surpassing any approved GLP-1 monotherapy. The SURPASS program for T2DM showed HbA1c reductions of 2.1-2.3% and weight loss of 12-14 kg, superior to semaglutide. This establishes that GIPR agonism adds substantially to GLP-1 agonism alone. The GIPR contribution to tirzepatide's benefit is estimated at approximately 5-8% additional weight loss beyond equivalent GLP-1 agonism.

The "impaired incretin effect" in type 2 diabetes, where oral glucose produces far less insulin secretion than IV glucose at matched blood glucose levels - is now understood to result primarily from GIP resistance (reduced GIPR signaling) rather than GLP-1 deficiency. Type 2 diabetic patients have normal GIP secretion but dramatically blunted beta-cell response to GIP. This GIPR resistance is partially overcome by supraphysiologic GIPR agonism with tirzepatide analogs.

Multiple observational and interventional studies show GIP axis activity is positively correlated with bone mineral density. GIP infusion in postmenopausal women reduces bone resorption markers. Tirzepatide-treated patients show trends toward improved bone density not seen with equivalent GLP-1 monotherapy, attributable to GIPR bone effects. This positions dual GIPR/GLP-1 agonism as potentially superior to GLP-1 monotherapy for metabolic bone disease.